enGene LEGEND Trial Update - ENGENE THERAPEUTICS INC

Financial Performance:

• No specific revenue, earnings, or cash flow figures were disclosed, as the company is in the clinical development phase prior to commercialization.
• Market research estimates an addressable population of 20,000 high-risk BCG-unresponsive NMIBC patients, with a target of capturing 10% (2,000 patients) to generate $1 billion in net sales.
• Pricing strategy will likely align with the current market range of $500,000 to $700,000 per year, based on payer research showing strong reimbursement for NCCN 2A guideline-included therapies.

Guidance and Future Outlook:

• Plans to initiate a Biologics License Application (BLA) submission for delaminogene (detalimogene) before the end of the current year.
• Targets potential FDA approval for delaminogene in 2027.
• Aims to provide initial clinical data from the surfactant bladder rinse cohort in mid-2027, potentially leading to a supplemental BLA (sBLA).
• Long-term goal is to establish delaminogene as the first and only non-viral gene therapy for NMIBC, suitable for sequencing across the entire patient population and care settings.

Business Segments and Product Lines:

• Lead Candidate: Delaminogene varroplasmid (detalimogene), a non-viral plasmid gene therapy for high-risk BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC).
• Clinical Trial (Legend): Pivotal Cohort 1 enrolled 125 patients; 120 included in final efficacy analysis.
• Key Development: New Chief Medical Officer (Dr. Alec Goluboff) and Chief Legal Administrative Officer (Jason Duncan) appointed to support commercialization.
• Pipeline Expansion: Investigating a short surfactant bladder rinse to potentially improve efficacy, durability, and reduce dwell time to 30 minutes.
• Commercial Strategy: Planning a field force of 40-60 sales reps to target the ~11,000 urologists treating NMIBC, with 75% of patients treated in community settings.

Market and Competitive Landscape:

• Target Population: High-risk BCG-unresponsive NMIBC with carcinoma in situ (CIS), including patients ineligible for or declining cystectomy.
• Differentiation: First and only non-viral gene therapy; favorable storage (standard freezer/fridge), no BSL-2 handling requirements, and streamlined administration compared to viral competitors.
• Market Trends: The landscape is shifting toward bladder-sparing therapies and sequencing, driven by patient preference to avoid radical cystectomy (90% of patients would try anything to avoid it).
• Competition: Positioned against existing approved therapies (viral gene therapies, chemotherapy, immunotherapy) and investigational agents; noted for lower logistical barriers in community practices where 30% of providers struggle with viral therapy adoption.

Risks and Challenges:

• Regulatory Risk: Final approval is pending FDA review and potential sBLA for the surfactant cohort.
• Clinical Uncertainty: Durability data is still maturing (12-month landmark data improved to 24%), and long-term progression-free survival requires further observation.
• Reimbursement Risk: Potential impacts from changing CMS rules, specifically 340B hospital reimbursement reductions (ASP minus 28%).
• Market Access: Need to navigate complex payer dynamics and ensure coverage for a novel mechanism in a niche but highly unmet need space.

Management Commentary and Tone:

• Tone: Highly confident and positive; management expressed "delight" with the maturing data and alignment with FDA expectations.
• Key Messages: Emphasized the "best-in-class" tolerability profile with low discontinuation rates (1%) and in-class efficacy (56% anytime CR).
• Strategic Focus: Highlighted the "total product profile" combining clinical efficacy, ease of use, and economic value for community practices to drive broad adoption.

Analyst Questions and Answers:

• FDA Submission Status: Confirmed eligibility for submission; FDA views current clinical data as sufficient for filing without a specific "efficacy bar" beyond the totality of evidence.
• Data Maturity: Clarified that efficacy and durability improvements are strictly due to patient maturation and longer follow-up, not changes in patient selection criteria.
• Reinduction: Noted that ~20% of patients may require reinduction, which is a standard feature in this disease space to achieve the 12-month durable response milestone.
• Biomarkers: No retrospective biomarker data available yet; future plans include monitoring urine IL-12 levels to assess response.
• Use Cases: Confirmed suitability for both community and academic centers; treatment selection remains a shared decision based on patient phenotype and preferences.
• Pricing/Reimbursement: Too early for specific pricing guidance, but payer research suggests parity for therapies with NCCN 2A guidelines despite price increases.

Other Key Points:

• Safety Profile: Treatment-related adverse events (TRAEs) are generally mild (93% Grade 1-2), with a median resolution time of 6 days; no Grade 4+ events reported.
• Efficacy Metrics: Anytime Complete Response (CR) is 56%; 91% of responders achieved CR within the first assessment. 100% of responders who entered maintenance showed durable responses at the 12-month landmark.
• Logistical Advantages: Delaminogene requires no special infrastructure, procedure rooms, or urine bleaching precautions, reducing patient and provider burden compared to competitors requiring 60-minute to 12-hour dwell times and strict isolation.